Susquehanna International Group
NGNE icon

Susquehanna International Group’s Neurogene NGNE Stock Holding History

Susquehanna International Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,006
Closed -$522K – 13400
2025
Q2 		$389K Buy
26,006
+11,601
+81% +$182K ﹤0.01% 9760
2025
Q1 		$169K Sell
14,405
-60,373
-81% -$1.05M ﹤0.01% 11111
2024
Q4 		$1.71M Buy
74,778
+34,538
+86% +$1.29M ﹤0.01% 5668
2024
Q3 		$1.69M Sell
40,240
-525
-1% -$20.4K ﹤0.01% 5631
2024
Q2 		$1.48M Sell
40,765
-90,493
-69% -$3.19M ﹤0.01% 5700
2024
Q1 		$6.68M Buy
+131,258
New +$4.38M ﹤0.01% 3190
2023
Q4 		– Sell
-3,289
Closed -$52K – 12975
2023
Q3 		$52K Buy
+3,289
New +$48.6K ﹤0.01% 11287
2023
Q1 		– Sell
-1,328
Closed -$13.5K – 13171
2022
Q4 		$13.5K Buy
+1,328
New +$13.7K ﹤0.01% 11874
2022
Q3 		– Sell
-3,586
Closed -$74K – 13806
2022
Q2 		$74K Buy
+3,586
New +$87.5K ﹤0.01% 11727
2022
Q1 		– Sell
-1,493
Closed -$87.1K – 13644
2021
Q4 		$144K Buy
1,493
+126
+9% +$15.3K ﹤0.01% 11838
2021
Q3 		$198K Sell
1,367
-734
-35% -$112K ﹤0.01% 11491
2021
Q2 		$388K Buy
2,101
+1,180
+128% +$261K ﹤0.01% 10209
2021
Q1 		$227K Buy
921
+415
+82% +$106K ﹤0.01% 11164
2020
Q4 		$143K Sell
506
-140
-22% -$34.2K ﹤0.01% 10277
2020
Q3 		$155K Buy
+646
New +$156K ﹤0.01% 9655
2018
Q3 		– Sell
-2,515
Closed -$133K – 9902
2018
Q2 		$133K Sell
2,515
-1,307
-34% -$341K ﹤0.01% 8921
2018
Q1 		$1.08M Buy
3,822
+1,739
+83% +$480K ﹤0.01% 5075
2017
Q4 		$490K Buy
2,083
+1,454
+231% +$341K ﹤0.01% 6670
2017
Q3 		$178K Buy
+629
New +$181K ﹤0.01% 8100
2016
Q3 		– Sell
-1,192
Closed -$240K – 8824
2016
Q2 		$157K Buy
+1,192
New +$189K ﹤0.01% 7791

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Susquehanna International Group's NGNE Position: Q3 2025 in Review

Susquehanna International Group sold out of Neurogene (NGNE) in Q3 2025, closing a stake of 26,006 shares — an estimated $522K sold.

Susquehanna International Group first reported a position in NGNE in Q2 2016 and held it in 20 quarters. The position peaked at $6.68M in Q1 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q3 2025.

  • Susquehanna International Group reported no remaining Neurogene position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 26,006 Neurogene shares in Q3 2025, an estimated $522K.
  • Susquehanna International Group first reported a position in Neurogene in Q2 2016 and held it in 20 quarters.
  • Susquehanna International Group's Neurogene position peaked at $6.68M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.